Updates in CRC: Applying Evidence to Clinical Practice

EP. 1: Starting with a Patient Case: 45yM high-risk T4N0 resected CRC - What are next steps?

December 24th 2024

Panelists review a patient case of a 45 year old man with high-risk T4N0 resected CRC.

EP. 2: Patient Centered Approach: Important Patient Counseling Points regarding ctDNA results in CRC

January 3rd 2025

Panelists discuss important patient counseling points regarding ctDNA results in colorectal cancer (CRC), focusing on how to communicate the implications of these results for treatment decisions, prognosis, and personalized care planning.

EP. 3: Expert Perspectives: GALAXY Results from CIRUCLATE study - Is it Practice Changing?

January 14th 2025

Panelists discuss how the CIRCULATE study's GALAXY results demonstrate the potential impact of circulating tumor DNA analysis in guiding adjuvant therapy decisions for stage II colon cancer patients, though further validation is needed before widespread clinical implementation.

EP. 4: Understanding ctDNA in Resected CRC: Transient vs. Sustained Clearance & Clinical Implications

January 21st 2025

Panelists discuss how patterns of ctDNA clearance in resected colorectal cancer patients - whether transient or sustained - can inform prognosis, guide treatment decisions, and predict disease recurrence risk.

EP. 5: Practical Considerations: Complexities with Utilizing ctDNA in CRC in the Real-World Practice Setting

January 28th 2025

Panelists discuss how to navigate real-world challenges in implementing ctDNA testing for colorectal cancer patients, including issues of test accessibility, result interpretation, insurance coverage, and integration into clinical workflows.

EP. 6: Exploring the NICHE-2 Trial: Neoadjuvant Immunotherapy in dMMR Colon Cancer

February 4th 2025

Panelists discuss how the NICHE-2 trial results demonstrate the potential benefits and implementation of neoadjuvant immunotherapy in patients with dMMR colon cancer, highlighting pathologic response rates and implications for treatment sequencing.

EP. 7: Final Insights: Emerging role of MRD and ctDNA testing in Colon Cancer

February 11th 2025

Panelists discuss how Minimal Residual Disease (MRD) and circulating tumor DNA (ctDNA) testing are revolutionizing colon cancer management through improved risk stratification, treatment selection, and surveillance strategies.